LOMBARDI, ROSA
LOMBARDI, ROSA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease
2026 R. Lombardi, F. Cinque, A. Cespiati, C. Bertelli, G. Pisano, G. Oberti, E. Fatta, J. Currà, E. Calzavara, F. Alletto, C. Garavaglia, G. Cincotto, A.L. Fracanzani, M. Gomaraschi
Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study
2026 Z.M. Younossi, L. De Avila, S. Petta, H. Hagström, S.U. Kim, A. Nakajima, J. Crespo, L. Castera, N. Alkhouri, M. Zheng, S. Treeprasertsuk, P. Ananchuensook, N. Shalimar, E. Tsochatzis, S.K. Trivikrama, L.K. Balakumaran, J. Fan, S.K. Roberts, K. Alswat, V. Wai-Sun Wong, Y. Yilmaz, W. Dunn, S. Francque, A. Cordie, M. Yu, M. Ekstedt, G. Boon-Bee Goh, C.P. Oliveira, M.G. Pessoa, W.K. Chan, M.I. Castellanos Fernandez, A. Duseja, J.P. Arab, G. Papatheodoridis, G. Sebastiani, C. Villela-Nogueira, R. D'Ambrosio, P. Lampertico, K.M. Alnaamani, A.G. Holleboom, A. Valsan, A. Venu, M. El-Kassas, G. Pennisi, Y. Shang, W. Liu, H.W. Lee, T. Kobayashi, S. Kakizaki, C. Caussy, B. Pearlman, P. Iruzubieta, R. Nadeem, F. Cinque, A. Neonaki, M. Zoncapé, R. Yang, S.J. Song, N. Dunn, Z. Gadi, M. Yeh, K. Kim-Jun Teh, S. Mahadeva, L.G. Fabian, A. Almohsen, N. Leite, N. Pugliese, J. Vessby, C. Xie, N.S. Choudhary, E. Friend, M. Poca, T. Kawaguchi, F.P. Russo, A. Gadano, L.A. Diaz, A.K. Singal, B. Segrestin, N. Gunn, D. Mauricio, M. Arrese, A. Fracanzani, R. Lombardi, A. Aghemo, B. Lam, A. Racila, S.A. Alqahtani, M. Stepanova
Two‐tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross‐sectional study
2026 A. Mantovani, R. Lombardi, A. Dalbeni, R. Morandin, M.G. Lando, V. Fiorio, N. Rolli, M. Forti, D. Messetti, M. Zoncape, I. Milani, M.E. Parrotta, D. Capoccia, V. Guglielmi, F. Leonetti, P. Sbraccia, A.L. Fracanzani, G. Targher
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
2025 M. Kalafateli, R. Forlano, E. Barnes, L. Martinez-Gili, M. Lacey, G. Sigon, B.H. Mullish, V. Mallet, L. Parlati, P. Richardson, N. Forde, G. Serviddio, R. Villani, S. Lens, M. Buti, E. Vargas, M. Viganò, A. Loglio, P. Lampertico, R. D'Ambrosio, S. Monico, G. Maffi, R. Lombardi, A.L. Fracanzani, C. De Luca, P. Ingiliz, A. Mangia, F. Leserre, A.M. Napolitano, V. Piazzolla, F.P. Russo, G. Raimondo, I. Cacciola, C. Saitta, M. Lemoine, G. Papatheodoridis, M. Papatheodoridi, D.N. Samonakis, D. O'Donnell, J. O'Donoghue, R.D. Abeles, N. Pugliese, A. Aghemo, M. Berenguer, A. Brown, M.R. Thursz, P. Manousou
Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques
2025 M. Longo, E. Paolini, M. Meroni, F. Cinque, C. Bertelli, G. Pisano, M. Maggioni, A.L. Fracanzani, R. Lombardi, P. Dongiovanni
Key predictors of relevant weight loss in patients with metabolic dysfunction-associated steatotic liver disease
2025 N. Pugliese, I. Arcari, F. Cerini, R. Lombardi, F. Turati, G. Pennisi, M. Soleri, S. Imone Rocchetto, D. De Deo, M. Sagasta, C. Masetti, A.L. Fracanzani, S. Petta, C. La Vecchia, M. Viganò, A. Aghemo
Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIII
2025 R. Lombardi, R. Forlano, G. Maffi, A. Cespiati, F. Cinque, D. Bignamini, P. Dongiovanni, P. Francione, G. Sigon, J. Huang, P. Manousou, F. Peyvandi, A. Tripodi, A.L. Fracanzani
Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework
2025 A. Dalbeni, M. Vicardi, L.A. Natola, F. Cattazzo, A. Auriemma, R. Lombardi, F. Cinque, L. Dalle Carbonare, A. Mantovani, D. Sacerdoti
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
2025 Z.M. Younossi, L. De Avila, S. Petta, H. Hagström, S. Up Kim, A. Nakajima, J. Crespo, L. Castera, N. Alkhouri, M. Zheng, S. Treeprasertsuk, P. Ananchuensook, Shalimar, E. Tsochatzis, S. Kotacherry Trivikrama, L. Kondarappassery Balakumaran, J. Fan, S.K. Roberts, K. Alswat, V. Wai-Sun Wong, Y. Yilmaz, W. Dunn, S. Francque, A. Cordie, M. Yu, M. Ekstedt, G. Boon-Bee Goh, C.P. Oliveira, M. Guimaraes Pessoa, W. Kheong Chan, M. Ivon Castellanos Fernandez, A. Duseja, J. Pablo Arab, G. Papatheodoridis, G. Sebastiani, C. Villela-Nogueira, R. D'Ambrosio, P. Lampertico, K. Alnaamani, A.G. Holleboom, A. Valsan, A. Venu, M. El-Kassas, G. Pennisi, Y. Shang, W. Liu, H. Won Lee, T. Kobayashi, S. Kakizaki, C. Caussy, B. Pearlman, P. Iruzubieta, R. Nadeem, F. Cinque, A. Neonaki, M. Zoncapé, R. Yang, S. Juan Song, N. Dunn, Z. Gadi, M. Yeh, K. Kim-Jun, S. Mahadeva, L. Gonzalez Fabian, A. Almohsen, N. Leite, N. Pugliese, J. Vessby, C. Xie, N. Singh Choudhary, E. Friend, M. Poca, T. Kawaguchi, F. Paolo Russo, A. Gadano, L. Antonio Diaz, A.K. Singal, B. Segrestin, N. Gunn, D. Mauricio, M. Arrese, A. Fracanzani, R. Lombardi, B. Lam, A. Racila, S.A. Alqahtani, M. Stepanova
Metabolic dysfunction associated steatotic liver disease (MASLD) treatment: Does lifestyle still matter?
2025 F. Cinque, A.L. Fracanzani, R. Lombardi
Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD
2025 M. Longo, E. Paolini, M. Meroni, M. Ripolone, L. Napoli, F. Gentile, A. Cespiati, E. Trombetta, R. Lombardi, M. Maggioni, A. Alisi, L. Miele, A. Liguori, G. Soardo, A. Gasbarrini, M. Moggio, A.L. Fracanzani, P. Dongiovanni
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study
2025 Z. M Younossi, L. De Avila, S. Petta, H. Hagström, S. Up Kim, A. Nakajima, J. Crespo, L. Castera, N. Alkhouri, M. Zheng, S. Treeprasertsuk, P. Ananchuensook, Shalimar, E. Tsochatzis, S. Kotacherry Trivikrama, L. Kondarappassery Balakumaran, J. Fan, S. K Roberts, K. Alswat, V. Wai-Sun Wong, Y. Yilmaz, W. Dunn, S. Francque, A. Cordie, M. Yu, M. Ekstedt, G. Boon-Bee Goh, C. P Oliveira, M. Guimaraes Pessoa, W. Kheong Chan, M. Ivon Castellanos Fernandez, A. Duseja, J. Pablo Arab, G. Papatheodoridis, G. Sebastiani, C. Villela-Nogueira, R. D'Ambrosio, P. Lampertico, K. M Alnaamani, A. G Holleboom, A. Valsan, A. Venu, M. El-Kassas, G. Pennisi, Y. Shang, W. Liu, H. Won Lee, T. Kobayashi, S. Kakizaki, C. Caussy, B. Pearlman, P. Iruzubieta, R. Nadeem, F. Cinque, A. Neonaki, M. Zoncapé, R. Yang, S. Juan Song, N. Dunn, Z. Gadi, M. Yeh, K. Kim-Jun Teh, S. Mahadeva, L. Gonzalez Fabian, A. Almohsen, N. Leite, N. Pugliese, J. Vessby, C. Xie, N. Singh Choudhary, E. Friend, M. Poca, T. Kawaguchi, F. Paolo Russo, A. Gadano, L. Antonio Diaz, A. K Singal, B. Segrestin, N. Gunn, D. Mauricio, M. Arrese, A. Fracanzani, R. Lombardi, B. Lam, A. Racila, S. A Alqahtani, M. Stepanova
Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals
2025 M. Shengir, W. Elgretli, F. Cinque, A.V. Ramanakumar, R. Lombardi, A. Cespiati, A.L. Fracanzani, L. Ballesteros, M. Deschenes, P. Wong, T. Chen, G. Sebastiani
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors
2024 R. Lombardi, A. Mantovani, A. Cespiati, P. Francione, G. Maffi, E. Del Zanna, C. Maffeis, A. Colecchia, N. Passigato, A. Ferrarese, C.D. Cusumanu, R. Villani, E. Orsi, V. Grancini, L. Airaghi, D. Bignamini, G. Serviddio, G. Targher, P. Dongiovanni, S. Fargion, A.L. Fracanzani
Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD
2024 M. Meroni, E. De Caro, F. Chiappori, M. Longo, E. Paolini, E. Mosca, I. Merelli, R. Lombardi, S. Badiali, M. Maggioni, A. Orro, A. Mezzelani, L. Valenti, A.L. Fracanzani, P. Dongiovanni
Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease
2024 R. Lombardi, A. Dalbeni, A. Mantovani, F. Ravaioli
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility
2024 N. Pugliese, D. Polverini, R. Lombardi, G. Pennisi, F. Ravaioli, A. Armandi, E. Buzzetti, A. Dalbeni, A. Liguori, A. Mantovani, R. Villani, I. Gardini, C. Hassan, L. Valenti, L. Miele, S. Petta, G. Sebastiani, A. Aghemo
The Negative Impact of Sarcopenia on Hepatocellular Carcinoma Treatment Outcomes
2024 A. Cespiati, D. Smith, R. Lombardi, A.L. Fracanzani
Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients
2024 A. Dalbeni, F. Cattazzo, L. De Marco, M. Bevilacqua, M. Zoncapè, R. Lombardi, R. Stupia, A. Mantovani, D. Sacerdoti
Author's Reply: “Bacterial infections predispose to the development of portal vein thrombosis in patients with decompensated cirrhosis”
2024 A. Dalbeni, F. Cattazzo, L. De Marco, M. Bevilacqua, M. Zoncapè, R. Lombardi, R. Stupia, A. Mantovani, D. Sacerdoti